glp 1 agonist dementia Advances in Clinical and Experimental Medicine GLP-1 Medications Associated with Reduced
Description
Exenatide and lixisenatide remain relegated to cost-sensitive tender lots, preserving minimal but steady volume
More significant weight reduction typically becomes evident after several months of consistent use, with many patients achieving substantial results over a period of 68 weeks, or about 16 months
(2023) 46:S128S39
Back Holst, JJ (2007) 'The physiology of glucagon-like peptide 1', Physiology Review, 87, 14009-39
10.1056/NEJMoa1603827 66 MeierJ
